Abstract
Although atypical antipsychotics (AA) are the first-line treatments for patients with schizophrenia, for those aged 13-14 years, lurasidone is the only AA licensed. Besides, some AA are related with cardiometabolic events (CME) and lack adherence, generating significant clinical and economic consequences. The aim of this study is to estimate the budget impact (BI) of lurasidone in the management of adult and adolescent (13-17 years) patients with schizophrenia in Spain from a payer's perspective over a 3-years’ time horizon.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
